Summary
0JXI Chart
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
MDGL swings to a wider Q4 loss as expenses surge, but Rezdiffra sales top estimates and fuel revenue growth. The stock slides 11% in response to the mixed nature of the results.
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Madrigal (MDGL) Reports Q4 Loss, Beats Revenue Estimates
Madrigal (MDGL) came out with a quarterly loss of $2.57 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $2.71 per share a year ago.
Madrigal Pharmaceuticals, Inc. (0JXI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Madrigal Pharmaceuticals, Inc. ever had a stock split?
Madrigal Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | William J. Sibold CEO | LSE Exchange | US5588681057 ISIN |
| US Country | 528 Employees | 25 Jul 2016 Last Dividend | 25 Jul 2016 Last Split | 6 Feb 2007 IPO Date |
Overview
Madrigal Pharmaceuticals, Inc. is a forward-thinking clinical-stage biopharmaceutical company based in West Conshohocken, Pennsylvania. With a primary focus on addressing the significant unmet medical needs in non-alcoholic steatohepatitis (NASH), Madrigal Pharmaceuticals, Inc. is at the forefront of developing innovative therapeutic solutions. NASH, a more severe form of non-alcoholic fatty liver disease (NAFLD), is a major cause of liver disease worldwide, lacking effective FDA-approved treatments. This places Madrigal Pharmaceuticals in a critical position to potentially transform the treatment landscape for this challenging condition. The company’s commitment to pioneering research and clinical development underscores its dedication to improving patient outcomes in the NASH domain.
Products and Services
- Resmetirom
Madrigal Pharmaceuticals’ lead product candidate, resmetirom, is a testament to the company’s innovative approach in targeting complex liver diseases. Resmetirom is a liver-directed thyroid hormone receptor beta agonist specifically designed to address the root causes of NASH. The mechanism of action involves modulating liver fat metabolism, reducing liver fat, inflammation, and fibrosis, which are critical factors in the progression of NASH. Currently in Phase 3 clinical trials, resmetirom has shown promise in early studies, offering hope for a potential breakthrough therapy for patients suffering from this life-threatening condition. The ongoing research and development of resmetirom reflect Madrigal Pharmaceuticals’ dedication to scientific excellence and a patient-centered approach to healthcare.
